Vermillion Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage ... - Nasdaq

Vermillion Announces OVA1® (MIA) and OVERA® (MIA2G) Study and Coverage ...
Nasdaq
AUSTIN, Texas, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (NASDAQ:VRML), a bioanalytical-based women's health company focused on gynecologic disease, today announced a study agreement and coverage with Clalit Health Services in Israel ...en meer »